S&P Biotech SPDR


How to Profit in a $29 Billion “New Biotech” Sector

Back in the late 1960s and early 1970s, psychedelics drugs like LSD were still legal and could be researched.

But in 1968 when the federal government criminalized them, a lot of promising research stopped.

Now the spotlight is back on these drugs and the success they’ve shown in clinical trials for treating a range of mental health conditions.

This is not only great news for people suffering from these conditions, but also for savvy investors who’ll get in on the ground floor of a market that could be worth more than $29 billion by the end of the decade.

Here’s Shah with all the details….



Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector

Not every biotech company is doing well in the search for an effective COVID-19 vaccine or treatment.

And the latest firm to struggle is Eli Lilly, whose antibody clinical trial was paused due to failure to show any real results.

So today, Andrew's going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news…



The 3 Best Biotech Stocks to Buy for 2018

Investors looking for profits in the healthcare sector had a difficult time in 2017 if they weren't in biotech. The Health Care SPDR ETF only gained 13.15% last year, while the S&P 500 climbed 22.5% over the same time period.

But within the broader health care sector the SPDR S&P Biotech ETF returned a market-beating 43.36% in 2017, nearly double the broader S&P 500.

That's why today we'll show you the three best biotech stocks to buy for 2018.